Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 64

recruiting
3 968
countries
28
conditions
2 103

885 trials match your criteria

Study on the Safety and Effectiveness of Crinecerfont for Adults with Classic Congenital Adrenal Hyperplasia

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Crinecerfont

Plasma cell myeloma

Not recruiting

Study of Durbactagene Autoleucel and Drug Combination for Adults with Relapsed and Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bendamustine

Study Comparing Romiplostim and Dexamethasone with Dexamethasone Alone for Patients with Newly Diagnosed Primary Immune Thrombocytopenia

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Romiplostim

Breast cancer+1

Not recruiting

Study of ribociclib combined with hormone therapy for patients with early-stage hormone receptor-positive, HER2-negative breast cancer

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole

Study on Batoclimab for Patients with Thyroid Eye Disease

InvestigationalNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Batoclimab

Glioma

Not recruiting

Study of Vorasidenib for Patients with Residual or Recurrent Grade 2 Glioma with IDH1 or IDH2 Mutation

Investigational
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Vorasidenib

Study Comparing Teclistamab with Daratumumab, Pomalidomide, and Dexamethasone for Patients with Relapsed or Refractory Multiple Myeloma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Bortezomib

Study on Trastuzumab and Pertuzumab for Patients with HER2-Positive Breast Cancer Using a Response-Adapted Strategy

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin

Study on the Safety and Effectiveness of ABSK021 for Patients with Tenosynovial Giant Cell Tumor

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Absk021 Hydrochloride Hydrate

Plasma cell myeloma

Not recruiting

Study Comparing Idecabtagene Vicleucel and Lenalidomide Maintenance Therapy for Adults with Newly Diagnosed Multiple Myeloma After Stem Cell Transplant

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Lenalidomide

Huntington's disease

Not recruiting

Study on Long-Term Safety and Effects of PTC518 for Patients with Huntington's Disease

Investigational
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:VOTOPLAM
Countries:ItalyItaly
  • Participants:18–64 years
  • Substances:Secukinumab
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.